- Home
- » Tags
- » Moroctocog alfa
Top View
- (INN) for Biological and Biotechnological Substances
- Refacto AF, INN-Moroctocog Alfa
- WHO Drug Information Vol
- Refacto AF, INN-Moroctocog Alfa
- Pharmacological Drugs Inducing Ototoxicity, Vestibular Symptoms and Tinnitus: a Reasoned and Updated Guide
- Challenges Facing Biosimilar Entries Into US Markets by Sarfaraz K
- Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahr 2020
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Clinical Efficacy and Safety of Moroctocog Alfa
- Xyntha Datasheet
- International Nonproprietary Names for Biological and Biotechnological Substances: a Review17
- Therapeutic Proteins: Blood Products, Vaccines and Enzymes
- Customs Tariff - Schedule
- (CHMP) Agenda for the Meeting on 21-24 June 2021
- Recent Progress in Biopharmaceutical Drugs Research and Development
- Ptr-Novembre-2020.Pdf
- Clinical Evaluation of Moroctocog Alfa (AF-CC), a New Generation of B-Domain Deleted Recombinant Factor VIII (Bddrfviii) For
- (M) of SARS-Cov-2
- FINAL PROGRAM Cairo, Egypt / Grand Hyatt
- XYNTHA® Moroctocog Alfa Rch, Also Known As Recombinant Coagulation Factor VIII Consumer Medicine Information
- Study Protocol);
- Patented Drug Products for Human Use Reported to the Pmprb 2011* January 1 – December 31, 2011
- Refacto, INN- Moroctocog Alfa
- Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits
- Estimating the Cost-Effectiveness of Belimumab Versus Standard Care For
- Optimal Use of Clotting Factors and Immunoglobulins
- Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management
- Minutes of the PRAC Meeting 2-5 May 2017
- Minutes of PRAC Meeting on 01-04 October 2018
- Minutes of the CHMP Meeting 21-24 June 2021
- Kidzpartners Formulary
- Bddrfviii (Moroctocog Alfa [AF-CC]) for Surgical Haemostasis in Patients with Haemophilia A: Results of a Pivotal Study
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Minutes of the PRAC Meeting 6-9 March 2017
- Using Pharmacokinetics for Tailoring Prophylaxis in People with Hemophilia Switching Between Clotting Factor Products: a Scoping Review
- Hematology Drugs in the Pipeline
- PRAC Minutes July 2016
- Blue Rx Essentialssm Formulary
- Turoctocog Alfa Pegol Provides Effective Management
- PMPRB Annual Report 2017 PMPRB PATENTED MEDICINES for HUMAN USE REPORTED to the PMPRB in 2017∗ JANUARY 1 – DECEMBER 31, 2017
- Novel Treatments in Haemophilia and Other Bleeding Disorders: a Periodic EHC Review 2021 Issue One
- Circumventing Furin Enhances Factor VIII Biological Activity and Ameliorates Bleeding Phenotypes in Hemophilia Models
- WO 2011/157283 Al O
- Consumo Anual Del Tratamiento Profiláctico Para La Hemofilia a Grave En Pacientes Adolescentes Y Adultos En España
- (Jivi®) En Hemofilia A
- Refacto AF, INN-Moroctocog Alfa (AF-CC)
- Peerview .Com /QUN900 Ensuring the Rapid Recognition and Optimal
- Esperoct (Turoctocog Alfa Pegol) Treatment of Haemophilia a EU/3/12/995 Sponsor: Novo Nordisk A/S
- Anlage B Teil 1: Wirtschaftlichkeit Der Arzneimittel Zur Spezifischen Therapie Von Gerinnungsstörungen Bei Hämophilie Farbliche Kennzeichnung Der Wirtschaftlichkeit
- Blue Rx Valuesm Formulary
- Joint Formulary for Hull and East Riding of Yorkshire
- A Single Country, Multicenter, Open-Label
- Novel Treatments in Haemophilia and Other Bleeding Disorders: a Periodic EHC Review 2020 Issue Two
- Factor VIII 1067 3
- Minutes of the PRAC Meeting 6-9 February 2017
- August 2021 L.A. Care Health Plan Medi-Cal Formulary